Review
Oncology
Shujie Zhou, Jingjing Xie, Zhaoqin Huang, Liufu Deng, Leilei Wu, Jinming Yu, Xiangjiao Meng
Summary: The brain is a common metastatic site in non-small cell lung cancer (NSCLC), and anti-PD-(L)1 immunotherapy shows potential efficacy against brain metastases in NSCLC patients. However, due to issues with the blood-brain barrier, the mechanisms of action and efficacy of these treatments remain unclear.
Article
Biochemistry & Molecular Biology
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse
Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.
Review
Oncology
Yan Wang, Xue Yang, Nan-Jing Li, Jian-Xin Xue
Summary: Leptomeningeal metastasis (LM) is a rare and highly fatal complication of non-small cell lung cancer (NSCLC). Improving the diagnosis and treatment of LM is crucial, as it severely affects patients' quality of life. Understanding the potential mechanisms of LM is helpful in addressing this issue. Clinical manifestations, magnetic resonance imaging, and CSF biopsy are key components in the diagnosis, and CSF cytology should be combined with liquid biology. Treatment options for LM patients include radiotherapy, intrathecal treatment, targeted therapy, and immunotherapy.
Article
Oncology
Konstantinos Rounis, Marcus Skribek, Dimitrios Makrakis, Luigi De Petris, Sofia Agelaki, Simon Ekman, Georgios Tsakonas
Summary: The study identified parameters that may potentially influence the intracranial outcome of patients with advanced NSCLC and brain metastases receiving PD-1/PD-L1 monotherapy, suggesting that age, history of CNS radiotherapy, and primary brain metastatic disease could impact the IC disease control probability. There is a lack of biomarkers for predicting intracranial outcomes in NSCLC patients with BM treated with ICIs, highlighting the need for further research in this area.
Review
Biochemistry & Molecular Biology
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel
Summary: Lung cancer is a common malignant neoplasm that may progress to metastasize to the central nervous system, affecting the prognosis unfavorably. The discovery of EGFR-activating mutations and ALK rearrangements in lung adenocarcinoma patients has led to the introduction of small-molecule tyrosine kinase inhibitors for advanced-stage treatment. These inhibitors target different pathways to improve progression-free survival in patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Tomoiki Aiba, Chieko Hattori, Jun Sugisaka, Hisashi Shimizu, Hirotaka Ono, Yutaka Domeki, Ryohei Saito, Sachiko Kawana, Yosuke Kawashima, Keisuke Terayama, Yukihiro Toi, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Yutaka Suzuki, Atsushi Niida, Shunichi Sugawara
Summary: By conducting whole-transcriptome sequencing of NSCLC patient samples, we found that tumors in LUAD patients are inherently immunogenic, while those in LUSC patients have a less immunosuppressive tumor microenvironment. This suggests that nivolumab may act as a molecular targeted agent in LUAD and as an immunomodulating agent in LUSC.
Article
Multidisciplinary Sciences
Ou Yamaguchi, Kyoichi Kaira, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Kazunari Tateishi, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Shun Shinomiya, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka, Tamotsu Ishizuka, Koichi Minato, Satoshi Suda, Hiroshi Kagamu, Keita Mori, Ichiei Kuji, Nobuhiko Seki
Summary: This study aimed to investigate the clinical relevance of F-18-FDG PET/CT compared to CT in predicting the response to PD-1 blockade in the early phase. The results showed that metabolic assessment by MTV or TLG was superior to morphological changes on CT for predicting the therapeutic response and survival.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Jia Luo, Victoria L. Martucci, Zoe Quandt, Stefan Groha, Megan H. Murray, Christine M. Lovly, Hira Rizvi, Jacklynn Egger, Andrew J. Plodkowski, Mohsen Abu-Akeel, Isabell Schulze, Taha Merghoub, Eduardo Cardenas, Scott Huntsman, Min Li, Donglei Hu, Matthew A. Gubens, Alexander Gusev, Melinda C. Aldrich, Matthew D. Hellmann, Elad Ziv
Summary: Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor therapy. Thyroid immune-related adverse events were associated with response to anti-PD-1 therapy, and genetic risk for hypothyroidism was associated with the risk of developing thyroid irAEs.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Gonca Ozcan, Meghana Singh, James J. Vredenburgh
Summary: Leptomeningeal metastasis (LM) is a severe complication of metastatic cancer that occurs when neoplastic cells invade the meningeal space. Diagnosis of LM is challenging due to diverse initial symptoms and requires thorough examination, CSF analysis, and MRI. Liquid biopsy of CSF has increased sensitivity for detecting tumor cells. Management of LM in NSCLC requires an individualized approach with surgery, radiation, chemotherapy, targeted agents, and immunotherapy. Targeting actionable mutations in LM, such as EGFR inhibitors, has shown promising results. Though limited, immunotherapy has shown potential in case reports. This review focuses on epidemiology, pathophysiology, diagnosis, and treatment strategies of LM in NSCLC, with emphasis on novel agents.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Luca Cantini, Federica Pecci, Daan P. Hurkmans, Robert A. Belderbos, Andrea Lanese, Cecilia Copparoni, Sophie Aerts, Robin Cornelissen, Daphne W. Dumoulin, Ilaria Fiordoliva, Silvia Rinaldi, Joachim G. J. V. Aerts, Rossana Berardi
Summary: The study suggests that statins are associated with better clinical outcomes in patients with malignant pleural mesothelioma and advanced non-small cell lung cancer treated with PD-1 inhibitors, and this association is dose-dependent.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Richard S. P. Huang, Lukas Harries, Brennan Decker, Matthew C. Hiemenz, Karthikeyan Murugesan, James Creeden, Khaled Tolba, Laura P. Stabile, Shakti H. Ramkissoon, Timothy F. Burns, Jeffrey S. Ross
Summary: This article examines the genomic landscape of NSCLC brain metastases samples with comprehensive genomic profiling. The study found targetable genomic alterations in NSCLC-BM patients, which can inform future clinical studies and suggest the use of brain tissue or cerebral spinal fluid specimens for personalized treatment optimization.
Article
Immunology
Yuwen Zhou, Ruolan Xia, Huilang Xiao, Dan Pu, Yixiu Long, Zhenyu Ding, Jiyan Liu, Xuelei Ma
Summary: In advanced NSCLC patients treated with PD-1 inhibitors, the presence of TFA-irAEs was associated with longer overall survival and progression free survival. Thyroid function abnormality may serve as a biomarker for antitumor immune response.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Oncology
Lumeng Luo, Peiyi Liu, Kuaile Zhao, Weixin Zhao, Xiaofei Zhang
Summary: Brain metastasis of non-small cell lung cancer is associated with specific immune microenvironment distinct from extracranial lesions. The differences in immune microenvironment between brain metastases and primary lung foci were highlighted in this review.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Martin Reck, Delvys Rodriguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csoszi, Andrea Fulop, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Ticiana A. Leal, Jonathan W. Riess, Erin Jensen, Bin Zhao, M. Catherine Pietanza, Julie R. Brahmer
Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Hui Zhang, Yong Wang, Huaguo Wu, Shizhen Zhou, Shuo Li, Xiangji Meng, Rongjie Tao, Jinming Yu
Summary: In this case study, the combination treatment of olaparib and dacomitinib showed efficacy in a lung cancer patient with osimertinib-resistant brain and leptomeningeal metastases. This provides a new treatment option for leptomeningeal metastases after osimertinib resistance.
FRONTIERS IN ONCOLOGY
(2022)
Article
Dermatology
Noa Kremer, Helena Martinez, Yael Anne Leshem, Emmilia Hodak, Alona Zer, Baruch Brenner, Iris Amitay-Laish
Summary: This study evaluated trichoscopic findings in scalp and facial hair of patients treated with EGFRI, revealing hair shaft anomalies as the most common change, along with increased thickness of eyebrows and eyelashes.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Oncology
Oded Icht, Liran Domachevsky, David Groshar, Elizabeth Dudnik, Ofer Rotem, Aaron M. Allen, Nir Peled, Daniel Reinhorn, Oded Jacobi, Tzippy Shochat, Hanna Bernstine, Alona Zer
Summary: Patients with low tumor burden showed higher response rates, longer progression-free survival (PFS) and overall survival (OS) when treated with ICI. These results may help improve patient selection for single-agent ICI therapy and further prospective analysis is warranted.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Elizabeth Dudnik, Mor Moskovitz, Abed Agbarya, Teodor Gottfried, Tzippy Shochat, Damien Urban, Alona Zer, Ofer Rotem, Assaf Moore, Shlomit Yust, Nir Peled, Mira Wollner, Jair Bar
Summary: In patients with advanced nonsmall cell lung cancer, continuing nivolumab treatment for over 24 months can improve progression-free survival. Continuing nivolumab at a standard dose until disease progression or intolerable toxicity remains the standard treatment option.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Dermatology
Iris Amitay-Laish, Hadas Prag-Naveh, Ayelet Ollech, Batya Davidovici, Yael Anne Leshem, Igor Snast, Aron Popovtzer, Ofer Purim, Dov Flex, Michael David, Baruch Brenner, Irit Ben-Aharon, Nir Peled, Emmillia Hodak, Salomon M. Stemmer
Summary: A randomized trial showed that prophylactic topical treatment with chloramphenicol 3% + prednisolone 0.5% ointment was more effective in treating EGFRI-induced facial papulopustular rash compared to aqua cream, reducing the incidence of protocol-specified significant rash.
Article
Clinical Neurology
Assaf Moore, Shlomit Yust-Katz, Oded Icht, Ruth Eliyahou, Noa Gordon, Aharon Yehonatan Cohen, Iris Magdalena Goldstein, Nir Peled, Tali Seigal, Alexandra Amiel, Elizabeth Dudnik
Summary: The study evaluated the efficacy and safety of bevacizumab in treating SRS-induced RN in NSCLC patients receiving ICI. Results showed that bevacizumab treatment was effective in improving symptoms, radiological findings, and reducing corticosteroid dose.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2021)
Article
Oncology
Marisa Bittoni, James Chih-Hsin Yang, Jin-Yuan Shih, Nir Peled, Egbert F. Smit, D. Ross Camidge, Rajeswara Rao Arasada, Dina Oksen, Emmanuelle Boutmy, Christopher Stroh, Andreas Johne, David P. Carbone, Paul K. Paik
Summary: This study aimed to describe characteristics, treatment, and outcomes of NSCLC patients with MET alterations in real-world clinical care. Results showed heterogeneous treatments between METamp and METex14 patients, with METamp patients more likely to have concomitant oncogenic mutations. Older age and non-smoking status were more common in METex14 patients, and MET targeted therapies could be beneficial for these rare alterations.
Article
Pharmacology & Pharmacy
Vered Fuchs, Waleed Kian, Rachel Lichtenberg, Jonah M. Cooper, Areen A. Remilah, Daniel Levin, Nir Peled, Laila C. Roisman
Summary: This study describes a case series of six patients with EGFRm NSCLC who were rechallenged with osimertinib following carboplatin-based chemotherapy. The results suggest that osimertinib rechallenge may be an effective and well-tolerated treatment approach, potentially improving survival by a few months.
CLINICAL DRUG INVESTIGATION
(2022)
Review
Oncology
Waleed Kian, Melanie Zemel, Dina Levitas, Wafeek Alguayn, Areen A. Remilah, Nader Abdel Rahman, Nir Peled
Summary: The effectiveness of LDCT screening in Europe needs to be re-evaluated, and potential future approaches for LC screening guidelines should be explored.
CURRENT OPINION IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Waleed Kian, Melanie Zemel, Emily H. Kestenbaum, Keren Rouvinov, Wafeek Alguayn, Dina Levitas, Anna Ievko, Regina Michlin, Moataz A. Abod, Ismaell Massalha, Elena Chernomordikov, Adam A. Sharb, Walid Shalata, Esther Levison, Laila C. Roisman, Konstantin Lavrenkov, Nir Peled, Lior Nesher, Alexander Yakobson
Summary: This study reviewed the charts of 210 cancer patients who received the BNT162b2 mRNA COVID-19 vaccine. The results showed that 65 participants experienced mild to moderate side effects, but there was no correlation between treatment protocol type or the timing of vaccine administration and the occurrence of side effects. Six participants were hospitalized and four died. The incidence of side effects in cancer patients was similar to that in the general public.
Article
Engineering, Biomedical
Ishita Basu, Ali Yousefi, Britni Crocker, Rina Zelmann, Angelique C. Paulk, Noam Peled, Kristen K. Ellard, Daniel S. Weisholtz, G. Rees Cosgrove, Thilo Deckersbach, Uri T. Eden, Emad N. Eskandar, Darin D. Dougherty, Sydney S. Cash, Alik S. Widge
Summary: This study demonstrates that closed-loop electrical stimulation of the internal capsule can enhance cognitive control in participants with epilepsy. Decoding of task performance from electrode activity was also achieved. These findings have the potential to improve cognitive deficits in individuals with severe mental disorders.
NATURE BIOMEDICAL ENGINEERING
(2023)
Article
Engineering, Biomedical
Sandeep Avvaru, Noam Peled, Nicole R. Provenza, Alik S. Widge, Keshab K. Parhi
Summary: Research suggests that direct electrical brain stimulation can enhance cognitive control and decision-making, with a novel method called MVNM effectively detecting cognitive control deficits. Effective networks can differentiate task engagement from background neural activity, while task engagement networks highlight the crucial role of the dlPFC in cognitive tasks.
IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
(2021)
Review
Oncology
Nir Peled, Vered Fuchs, Emily H. Kestenbaum, Elron Oscar, Raul Bitran
Summary: Lung cancer has been the leading cause of cancer-related deaths historically, with a lack of early screening and diagnostic methods. Recent efforts have focused on identifying a biomarker to detect early metabolic changes in carcinogenesis.
LUNG CANCER-TARGETS AND THERAPY
(2021)
Article
Oncology
Walid Shalata, Muhammed Iraqi, Baisali Bhattacharya, Vered Fuchs, Laila C. Roisman, Ahron Yehonatan Cohen, Ismaell Massalha, Alexander Yakobson, Manu Prasad, Moshe Elkabets, Angel Porgador, Nir Peled
Summary: The study demonstrated the advantage of treating different carcinoma types with a combination of lenvatinib and pembrolizumab, showing enhanced response to therapy. The combination of these two drugs may have great potential as a treatment option for patients with non-small cell lung carcinoma and malignant pleural mesothelioma. This new era of cancer treatments has significantly improved patient prognoses by using immune checkpoint inhibitors and multikinase inhibitors as standards of care.
Article
Oncology
Alexander Yakobson, Wafeek Alguayn, Walid Shalata, Daniel Levin, Tawfeek A. Kian, Amir Korngreen, Rachel Gibbs, Mahmuod A. Salah, Benzion Samueli, Konstantin Lavrenkov, Laila C. Roisman, Yulia Dudnik, Nir Peled, Yael Refaely, Waleed Kian
Summary: Epithelioid hemangioma (EH) and epithelioid hemangioendothelioma (EHE) are both rare vascular tumors, with EH usually benign and EHE having moderate malignant potential. Treatment challenges arise from their rarity and lack of guidelines, with proposed approaches including pazopanib and minimally invasive surgical resection.
CASE REPORTS IN ONCOLOGY
(2021)